242 related articles for article (PubMed ID: 15002032)
1. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
2. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
4. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
5. Augmented antitumor activity of a secondary lymphoid-tissue chemokine (SLC)-interleukin (IL) 2 fusion protein in mouse.
Nakahara K; Sakata T
J Gene Med; 2003 Jun; 5(6):463-71. PubMed ID: 12797111
[TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
7. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
10. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Sharma S; Stolina M; Zhu L; Lin Y; Batra R; Huang M; Strieter R; Dubinett SM
Cancer Res; 2001 Sep; 61(17):6406-12. PubMed ID: 11522634
[TBL] [Abstract][Full Text] [Related]
11. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
12. [Effects of hMIP-1beta gene modification on in vivo tumorigenicity and vaccine efficacy of tumor cells].
Luo XL; Xie YA; Kuang ZP; Wu JN; Liang AM
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):97-102. PubMed ID: 18646689
[TBL] [Abstract][Full Text] [Related]
13. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
14. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
15. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
16. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Yang SC; Batra RK; Hillinger S; Reckamp KL; Strieter RM; Dubinett SM; Sharma S
Cancer Res; 2006 Mar; 66(6):3205-13. PubMed ID: 16540672
[TBL] [Abstract][Full Text] [Related]
17. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Tang L; Hu HD; Hu P; Lan YH; Peng ML; Chen M; Ren H
Gene Ther; 2007 Aug; 14(16):1226-34. PubMed ID: 17597794
[TBL] [Abstract][Full Text] [Related]
19. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
Yang X; Chu Y; Wang Y; Zhang R; Xiong S
J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]